Isolation and Characterization of φkm18p, a Novel Lytic Phage with Therapeutic Potential against Extensively Drug Resistant Acinetobacter baumannii

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Shen, Gwan Han ^a,b   Wang, Jiun Ling ^c,d   Wen, Fu Shyan ^e   Chang, Kai Ming ^e   Kuo, Chih Feng ^c   Lin, Chun Hung ^c   Luo, Huei Ru ^c   Hung, Chih Hsin ^c  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

^d E DA HOSPITAL   (Taiwan)

^e NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA;

ACINETOBACTER BAUMANNII; ARTICLE; BACTERIOPHAGE; BACTERIOPHAGE PHI314; BACTERIOPHAGE PHIKM18P; BACTERIOPHAGE PHITZ1; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CELL SURVIVAL; COLONY FORMING UNIT; CONTROLLED STUDY; EPITHELIUM CELL; GENETIC CODE; GENOME SIZE; GENOTYPE; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; MICROBIAL POPULATION DYNAMICS; NEW SPECIES; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; SURVIVAL RATE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTERIOLYSIS; BACTERIOPHAGES; BIOLOGICAL THERAPY; CELL LINE; CELL SURVIVAL; DNA, VIRAL; DRUG RESISTANCE, BACTERIAL; ENDOPEPTIDASES; GENOME, VIRAL; HUMANS; RESTRICTION MAPPING; SEWAGE; VIRAL PROTEINS; VIRAL TROPISM;

ACINETOBACTER BAUMANNII; BACTERIA (MICROORGANISMS);

EID: 84867151466     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046537     Document Type: Article

References (48)

1. Cisneros JM, Rodriguez-Bano J, Fernandez-Cuenca F, Ribera A, Vila J, et al. (2005) Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. Clin Microbiol Infect 11: 874-879.
2. Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, et al. (2007) Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 13: 97-103.
3. Garnacho-Montero J, Amaya-Villar R, (2010) Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 23: 332-339.
4. Karageorgopoulos DE, Falagas ME, (2008) Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 8: 751-762.
5. Hsueh PR, Teng LJ, Chen CY, Chen WH, Yu CJ, et al. (2002) Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 8: 827-832.
6. Giske CG, Monnet DL, Cars O, Carmeli Y, (2008) Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 52: 813-821.
7. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, et al. (2012) Multidrug-resistant,extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18: 268-281.
8. Alisky J, Iczkowski K, Rapoport A, Troitsky N, (1998) Bacteriophages show promise as antimicrobial agents. J Infect 36: 5-15.
9. Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T, et al. (2005) Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 11: 211-219.
10. Sulakvelidze A, Alavidze Z, Morris JG Jr, (2001) Bacteriophage therapy. Antimicrob Agents Chemother 45: 649-659.
11. Summers WC, (2001) Bacteriophage therapy. Annu Rev Microbiol 55: 437-451.
12. Anisimov AP, Amoako KK, (2006) Treatment of plague: promising alternatives to antibiotics. J Med Microbiol 55: 1461-1475.
13. Fortuna W, Miedzybrodzki R, Weber-Dabrowska B, Gorski A, (2008) Bacteriophage therapy in children: facts and prospects. Med Sci Monit 14: RA126-132.
14. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, et al. (2002) Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 70: 204-210.
15. Barrow P, Lovell M, Berchieri A Jr, (1998) Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin Diagn Lab Immunol 5: 294-298.
16. Vinodkumar CS, Kalsurmath S, Neelagund YF, (2008) Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice. Indian J Pathol Microbiol 51: 360-366.
17. Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, et al. (2007) Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 51: 446-452.
18. Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, et al. (2003) Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis 187: 613-624.
19. Cerveny KE, Depaola A, Duckworth DH, Gulig PA, (2002) Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice. Infect Immun 70: 6251-6262.
20. Lang LH, (2006) FDA approves use of bacteriophages to be added to meat and poultry products. Gastroenterology 131: 1370.
21. Guenther S, Huwyler D, Richard S, Loessner MJ, (2009) Virulent bacteriophage for efficient biocontrol of Listeria monocytogenes in ready-to-eat foods. Appl Environ Microbiol 75: 93-100.
22. Herman NJ, Juni E, (1974) Isolation and characterization of a generalized transducing bacteriophage for Acinetobacter. J Virol 13: 46-52.
23. Ackermann HW, Brochu G, Emadi Konjin HP, (1994) Classification of Acinetobacter phages. Arch Virol 135: 345-354.
24. Bouvet PJ, Jeanjean S, Vieu JF, Dijkshoorn L, (1990) Species, biotype, and bacteriophage type determinations compared with cell envelope protein profiles for typing Acinetobacter strains. J Clin Microbiol 28: 170-176.
25. Joly-Guillou ML, Bergogne-Berezin E, Vieu JF, (1990) A study of the relationships between antibiotic resistance phenotypes, phage-typing and biotyping of 117 clinical isolates of Acinetobacter spp. J Hosp Infect 16: 49-58.
26. Soothill JS, (1992) Treatment of experimental infections of mice with bacteriophages. J Med Microbiol 37: 258-261.
27. Klovins J, Overbeek GP, Van Den Worm SH, Ackermann HW, Van Duin J, (2002) Nucleotide sequence of a ssRNA phage from Acinetobacter: kinship to coliphages. J Gen Virol 83: 1523-1533.
28. Weiss BD, Capage MA, Kessel M, Benson SA, (1994) Isolation and characterization of a generalized transducing phage for Xanthomonas campestris pv. campestris. J Bacteriol 176: 3354-3359.
29. García P, Madera C, Martíez B, Rodríuez A, (2007) Biocontrol of Staphylococcus aureus in curd manufacturing processes using bacteriophages. International Dairy Journal 17: 1232-1239.
30. Tseng YH, Choy KT, Hung CH, Lin NT, Liu JY, et al. (1999) Chromosome map of Xanthomonas campestris pv. campestris 17 with locations of genes involved in xanthan gum synthesis and yellow pigmentation. J Bacteriol 181: 117-125.
31. Jyothisri K, Deepak V, Rajeswari MR, (1999) Purification and characterization of a major 40 kDa outer membrane protein of Acinetobacter baumannii. FEBS Lett 443: 57-60.
32. Kivelä HM, Kalkkinen N, Bamford DH, (2002) Bacteriophage PM2 has a protein capsid surrounding a spherical proteinaceous lipid core. J Virol 76: 8169-8178.
33. ICTVdB Management (2006) In: ICTVdB- The Universal Virus Database, version 4. Buchen-Osmond C, editor. New York: Columbia University. Available: http://www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/. Accessed 2012 Sep 14.
34. Brüssow H, (2005) Phage therapy: the Escherichia coli experience. Microbiol 151: 2133-2144.
35. Kocharunchitt C, Ross T, McNeil DL, (2009) Use of bacteriophages as biocontrol agents to control Salmonella associated with seed sprouts. Int J Food Microbiol 128: 453-9.
36. Vieira A, Silva YJ, Cunha A, Gomes NC, Ackermann HW, et al. (2012) Phage therapy to control multidrug-resistant Pseudomonas aeruginosa skin infections: in vitro and ex vivo experiments. Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-012-1691-x.
37. Gadakar R, Gopinathan KP, (1980) Bacteriophage burst size during multiple infections. J Biosci 2: 253-259.
38. Hyman P, Abedon ST (2009) Practical Methods for Determining Phage Growth Parameters. In: Clokie MRJ, Kropinski AM, editors. Bacteriophages: Methods and Protocols, Volume 1: Isolation, Characterization, and Interactions, vol. 501. New York: Humana Press. pp. 175-202.
39. Kudva IT, Jelacic S, Tarr PI, Youderian P, Hovde CJ, (1999) Biocontrol of Escherichia coli O157 with O157-specific bacteriophages. Appl Environ Microbiol 65: 3767-3773.
40. Carey-Smith GV, Billington C, Cornelius AJ, Hudson JA, Heinemann JA, (2006) Isolation and characterization of bacteriophages infecting Salmonella spp. FEMS Microbiol Lett 258: 182-186.
41. Fischer CR, Yoichi M, Unno H, Tanji Y, (2004) The coexistence of Escherichia coli serotype O157:H7 and its specific bacteriophage in continuous culture. FEMS Microbiol Lett 241: 171-177.
42. Mizoguchi K, Morita M, Fischer CR, Yoichi M, Tanji Y, et al. (2003) Coevolution of bacteriophage PP01 and Escherichia coli O157:H7 in continuous culture. Appl Environ Microbiol 69: 170-176.
43. Park SC, Shimamura I, Fukunaga M, Mori KI, Nakai T, (2000) Isolation of bacteriophages specific to a fish pathogen, Pseudomonas plecoglossicida, as a candidate for disease control. Appl Environ Microbiol 66: 1416-1422.
44. Young R, (1992) Bacteriophage lysis: mechanism and regulation. Microbiol Rev 56: 430-481.
45. Hartzell JD, Neff R, Ake J, Howard R, Olson S, et al. (2009) Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 48: 1724-1728.
46. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME, (2008) Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 62: 45-55.
47. Chhibber S, Kaur S, Kumari S, (2008) Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. J Med Microbiol 57: 1508-1513.
48. Tanji Y, Shimada T, Fukudomi H, Miyanaga K, Nakai Y, et al. (2005) Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice. J Biosci Bioeng 100: 280-287.